-
Innovent Biologics Collaborates with LG Chem for Tigulixostat in China
•
China-based Innovent Biologics (HKG: 1801) has announced a strategic collaboration and license agreement with South Korea firm LG Chem Life Sciences, obtaining exclusive development and commercialization rights to the latter’s tigulixostat in China. Innovent Bio will pay LG Chem a USD 10 million upfront payment and is committed to USD…
-
Alternative Bio Completes $15M Seed Round to Advance Cancer Therapeutics
•
Singapore-based Alternative Bio Inc. has announced the completion of a seed financing round at USD 15 million, co-led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund. The proceeds will be used to leverage an innovative discovery platform and advance the company’s lead drug candidates to treat…
-
Shanghai Pharmaceuticals Partners with HKSTP for Biomedicine Cultivation Program
•
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), Shanghai Biomedical Frontier Industry Innovation Center Co., Ltd, and Hong Kong Science & Technology Parks (HKSTP) announced a partnership to promote a biomedicine cultivation program in the HKSTP. No financial details were disclosed. Program Objectives and SupportThe program aims to attract the world’s top…
-
111 Inc. Begins Online Sales of Pfizer’s Paxlovid in China
•
China-based online pharmacy 111 Inc. (NASDAQ: YI) reportedly initiated online retail sales of Pfizer Inc.’s oral COVID-19 therapy Paxlovid (nirmatrelvir, ritonavir) in China. The price for one box covering a single course of treatment was set at RMB 2,980 (USD 428.23). 111 later released a statement noting that the drug…
-
Biosion and ImmunoGen Collaborate on Cancer ADCs
•
China-based Biosion Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the treatment of cancer with US firm ImmunoGen, Inc. (Nasdaq: IMGN). Biosion will leverage its proprietary SynTracer high-throughput (HT) endocytosis platform to generate highly selective antibodies to targets allocated by each company, and ImmunoGen will provide…
-
Abcam and Wuxi Diagnostics Expand Partnership into Companion Diagnostics
•
UK-headquartered Abcam plc. and China-based Wuxi Diagnostics have expanded their partnership to dive deep into the companion diagnostics (CDx) field. No financial details were disclosed. Abcam’s Role in Life Science ResearchAbcam is a global life science company supporting customers at the forefront of life science research, and is engaged in…
-
Henlius Biotech Partners with Medilink for Global ADC Development
•
Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with Suzhou-based Medilink Therapeutics, obtaining global development, manufacturing, and commercialization rights to antibody conjugate drugs (ADCs) based on the latter’s ADC technology platform, focusing on two designated, undisclosed targets. No financial details were revealed. Medilink’s ADC TechnologyMedilink Therapeutics boasts the…
-
Ascentage Pharma’s APG-2575 Shows Promising Results in Global Phase II Study
•
Suzhou-based Ascentage Pharma (HKG: 6855) unveiled preliminary data from the global Phase II clinical study for its APG-2575, alone or combined with Calquence (acalabrutinib) plus rituximab, in recurrent/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The results were released at the 64th American Society of Hematology (ASH) annual meeting this…
-
Lifetech Scientific Completes Enrollment for IBS Coronary Stent Phase II Study
•
China-based Lifetech Scientific Corporation (HKG: 1302) announced that all patients have been enrolled in a prospective, multi-center, randomized controlled Phase II clinical study for its IBS absorbable drug-eluting coronary stent system in China. Study Design and ResultsThe study, expected to involve upwards of 40 clinical centers across the country, is…
-
ImmuneOnco’s IMM2520 Receives FDA Clinical Trial Approval
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for its IMM2520, a bispecific antibody (BsAb) targeting CD47 and PD-L1 in solid tumors. Mechanism of Action and Preclinical ResultsIMM2520, featuring functional IgG1 Fc, can activate macrophages and T cells simultaneously by targeting CD47 and PD-L1…
-
Jiangsu Recbio’s COVID-19 Vaccine ReCOV Shows Superiority in Phase II Trial
•
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the positive results of a Phase II clinical study for its recombinant COVID-19 vaccine ReCOV in the Philippines as a sequential booster shot. The results showed that ReCOV as a sequential booster shot was superior to mRNA vaccine in…
-
Treadwell Therapeutics Presents PLK4 Inhibitor Data at ASH Annual Meeting
•
China-based Treadwell Therapeutics presented results of the company’s CFI-400945 program, a first-in-class inhibitor of Polo-like Kinase 4 (PLK4), a critical regulator of centriole duplication, at the 64th American Society of Hematology (ASH) annual meeting. The poster presentation described the preliminary results from the monotherapy dose optimization portion of the TWT-202…
-
Cryofocus Biotechnology’s RDN System Gains FDA Breakthrough Therapy Designation
•
Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd’s in-house developed Cryofocus RDN System, a cryoablation renal denervation product, has obtained breakthrough therapy designation (BTD) status from the US FDA for use in refractory hypertension. Regulatory Milestones and InnovationsThe Cryofocus RDN System, the first of its kind globally, previously passed…
-
Cutia Therapeutic Plans IPO on Hong Kong Stock Exchange
•
China-based dermatology specialist Cutia Therapeutic announced plans to make an initial public offering (IPO) to the Hong Kong Stock Exchange. Company Background and PipelineFounded in 2019, Cutia Therapeutic boasts a pipeline consisting of 11 products with great market potential, covering hair disease and hair care, skin disease and skin care,…
-
Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202
•
China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical study for its oral drug candidate APL-1202 in combination with the PD-1 inhibitor tislelizumab as a neoadjuvant therapy for muscular invasive bladder cancer (MIBC). The open-label, multi-center Phase I/II clinical study is designed to evaluate…
-
Jiangsu Yahong Administers First Dose of Hexvix in Hainan Pilot Zone
•
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) announced the first patient administration of Hexvix (hexyl aminolevulinate hydrochloride) in the Lecheng medical pilot zone in Hainan province. Hexvix is an optical imaging agent used to perform Blue Light Cystoscopy to detect carcinoma of the bladder for…
-
Ascletis Pharma Announces Positive Phase I Results for ASC10 in COVID-19 Treatment
•
China-based Ascletis Pharma Inc., (HKG: 1672) announced the positive topline results from its Phase I multiple ascending dose (MAD) study (NCT05523141) in healthy subjects for the oral RNA-dependent RNA polymerase (RdRp) inhibitor ASC10 being developed as treatment for COVID-19. The Phase I data demonstrated that all doses of ASC10, including…
-
Yantai Dongcheng to Acquire US Firm XingImaging for $30.2M
•
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) is set to acquire a 100% stake in US-based firm XingImaging LLC for a consideration of USD 30.2 million from sellers Gilles Tamagnan, Molecular Neuroimaging Holdings LLC, Kenneth Marek, Bill (Piu) Chan, David Alagille, Rebecca Evans, and Gu Zhuqin. XingImaging’s Focus…
-
Hotgen Biotech’s COVID-19 Antigen Home Test Approved in Russia
•
China-based Hotgen Biotech Co., Ltd (SHA: 688068) announced receiving market approval in Russia for its Hotgen COVID-19 antigen home test. The product, used for household testing of novel Coronavirus (2019-nCoV), previously received approvals in the US, the European Union, and the UK. Global Approvals and Market ExpansionHotgen Biotech’s COVID-19 antigen…
-
Angel Pharmaceuticals Presents CPI-818 Data at ASH 2022 Annual Meeting
•
China-based Angel Pharmaceuticals Ltd announced the latest results of the global Phase I/Ib clinical study for CPI-818, a first-in-class ITK inhibitor co-developed by US partner Corvus Pharmaceuticals, at the American Society of Hematology (ASH) 2022 annual meeting. The study has shown the anti-tumor activities in T-cell lymphoma (TCL), alongside therapeutic…
